Karyopharm announces xpovio® (selinexor) data to be presented at the european hematology association 2022 hybrid congress

Newton, mass. , may 12, 2022 /prnewswire/ -- karyopharm therapeutics inc. (nasdaq: kpti), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that initial data from a phase 1 portion of the ph 1/2 study evaluating selinexor in combination with ruxolitinib in patients with treatment-naÏve myelofibrosis has been selected for a poster presentation at the european hematology association (eha) 2022 hybrid congress taking place june 9-12, 2022, in vienna, austria.
KPTI Ratings Summary
KPTI Quant Ranking